Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.80 |
| ▸ | TP53 | P04637 | 8/20 | 0.80 |
| ▸ | LMNA | P02545 | 7/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264280 | 0.91 | MAPT (0.67) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL6265403 | 0.82 | LMNA (0.67) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL16777890 | 0.81 | MAPT (0.56) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL15153042 | 0.80 | LMNA (0.74) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL17085005 | 0.80 | TP53 (0.80) | MAPTTP53LMNA | |
| SCHEMBL15919648 | 0.79 | KMT2A (0.60) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL15277012 | 0.78 | TP53 (0.70) | MAPTTP53LMNA | |
| SCHEMBL14485063 | 0.78 | MAPT (0.69) | MAPTTP53LMNAKMT2AMEN1 | |
| SCHEMBL15613013 | 0.77 | MAPT (0.80) | MAPTTP53LMNAALDH1A1KMT2A | |
| SCHEMBL14484939 | 0.77 | MEN1 (0.76) | MAPTTP53LMNAALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | claimed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | claimed |
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-10-27 | — | — | US | claimed |
| WO-2005087217-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2005-09-22 | — | — | WO | claimed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885TP53 232/4885LMNA 1941/4885 |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885TP53 232/4885LMNA 1941/4885 |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885TP53 232/4885LMNA 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.